Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.62 |
| ▸ | CDK8 | P49336 | 3/20 | 0.62 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.62 |
| ▸ | SGK1 | O00141 | 2/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337207 | 0.89 | AXL (0.53) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL29337270 | 0.82 | SGK1 (0.83) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL3775002 | 0.79 | MAP3K11 (0.66) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL8941685 | 0.78 | AXL (1.00) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL8320028 | 0.76 | AXL (0.78) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL3771129 | 0.76 | SGK1 (1.00) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL1857492 | 0.75 | AXL (0.76) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL3761281 | 0.75 | AXL (0.76) | AXLCDK8TNIKSGK1IGF1R | |
| SCHEMBL29337149 | 0.75 | NTRK1 (0.90) | AXLCDK8TNIKSGK1NTRK1 | |
| SCHEMBL12572765 | 0.75 | AXL (0.76) | AXLCDK8TNIKSGK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239795-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239795-A1 | NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS | AXL, ABL1, ZC3HAV1 | AXL 1/4885CDK8 80/4885TNIK 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.